Abstract
sigmoidal drug release profile is formed when a pulsatile drug delivery system (PDDI) initiates drug administration and follows it up with rapid and complete drug release. It ensures the correct dosage of the drug is delivered at the right time and place. Pulsatile drug delivery is effective for treating asthma, arthritis, cancer, diabetes, epilepsy, hypertension, ulcers, and hypercholesterolemia, among others. There are many types of delivery systems in the pharmaceutical industry, including capsular, osmotic, single and multi-unit designs and membranes that are soluble and erodible. Innovations are directed toward conditions such as those requiring nocturnal dosing, high first-pass effects, and site-specific absorption in the gastrointestinal tract. In particular, these systems make dosing more convenient for patients, resulting in better compliance. As a result of the use of chronomodulated drug delivery systems, pharmaceutical therapy is more effective with a personalized approach.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
